Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Moderna Drops Plan for mRNA API Site in Japan as Vaccine Demand Slumps
Moderna has shelved plans to establish an mRNA API production site at Shonan Health Innovation Park (Shonan iPark) in Japan, citing the current market environment. The decision, announced on July 18, comes amid weak demand for vaccines. The US mRNA…
To read the full story
Related Article
- Moderna Ratchets Up Oncology Drive with Cancer Vaccine PIII Win
September 15, 2026
- Moderna Japan Looks Beyond COVID for Next Growth Pillars
June 9, 2026
- Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
- Moderna CEO Maintains Future Vision for Product Mix despite R&D Cutback, Eyes Leap with Flu-COVID Shot
October 18, 2024
BUSINESS
- Daiichi-AZ, Summit Team Up on Datroway Combo in Multiple Cancers
October 5, 2026
- Taiho, Cullinan Start US Filing for Zipalertinib-Chemo Combo
October 5, 2026
- Stargardt Diagnosis System Needs Bolstering as Treatment Nears: Expert
October 5, 2026
- Cheplapharm to Acquire MA for Kyowa Kirin’s 5-FU Products
October 5, 2026
- Nippon Kayaku Completes Buyout of Fuji’s Toyama Plant
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…